LONDON, March 6, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose dis ...

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

The retrospective cohort study included 114 patients (mean age, 50.6 years; 67.5% female) with eosinophilic granulomatosis with polyangiitis (EGPA) who used mepolizumab (Nucala, GSK).

GSK said that if approved, ... Known also as mepolizumab, Nucala was first approved in 2015 for a type of severe asthma in the United States. Its sales grew 12% to about 1.78 billion pounds ...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, ... (Funded by GSK; MATINEE ClinicalTrials.gov number, NCT04133909.) Quick Take. Mepolizumab to Prevent Exacerbations of ...

The safety of mepolizumab was found to be consistent with results from previous clinical trials. According to GSK, full study data from MATINEE will be presented at a future medical meeting.

First IL-5 therapy approved as an add-on treatment in the US for adults with chronic rhinosinusitis with nasal polyps to target eosinophilic inflammation Fourth indication for mepolizumab in the ...